Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma

Gao-Min Liu1,2, Qiao Li1, Peng-Fei Zhang3, Shun-Li Shen1, Wen-Xuan Xie1, Bin Chen1, Jian Wu1, Wen-Jie Hu1, Xiao-Yong Huang3 and Bao-Gang Peng1

Abstract
Fructose-1,6-bisphosphatase (FBP1), one of the rate-limiting gluconeogenic enzymes, plays critical roles in several cancers and is treated as a tumour suppressor. However, its role in hepatocellular carcinoma (HCC) is unclear. Here, we demonstrated that FBP1 was significantly inhibited during Snail-induced epithelial to mesenchymal transition (EMT) and tissues in HCC. Restoration of FBP1 expression in HCC cancer cells suppressed EMT phenotype, tumour migration and tumour growth induced by Snail overexpression in SMMC-7721 cells. Gene set enrichment analyses revealed significantly enriched terms, including WNT, Notch, ESC, CSR and PDGF, in the group with high Snail and low FBP1 compared with those with low Snail and high FBP1. Low FBP1 expression was significantly correlated with higher AFP level, satellite nodules, portal vein tumour thrombus, and advanced tumour stage. Survival analyses showed that FBP1 was an independent prognostic factor for overall survival and recurrence-free survival. In conclusion, our study revealed a vital role for FBP1 in Snail-induced EMT and prognostic prediction in HCC.

Introduction
Hepatocellular carcinoma (HCC) remains a global public health issue. It is ranked as the fifth leading cancer and the second leading cause of cancer-related mortality1. The long-term survival is far from satisfying due to the low rate of curative treatment and the high rate of post-curative recurrence. There is always an urgent demand for a better understanding of the molecular mechanisms underlying HCC2.

The ability of differentiated epithelial cells to acquire mesenchymal traits during embryonic development, wound healing, malignant tumour progression and chemoresistance is now termed epithelial–mesenchymal transition (EMT). Via EMT, cells acquire mesenchymal properties, such as expression of Vimentin, but at the same time lose the expression of epithelial markers, such as E-cadherin3. Snail is one of the most important transcription factors that drive EMT4,5. However, little is known about the role of aberrant glucose metabolism in Snail-induced EMT.

Glucose homeostasis is reciprocally controlled by the catabolic glycolysis/oxidative phosphorylation (OXPHOS) and the anabolic gluconeogenesis pathway. Aberrant glucose metabolism promotes tumourigenesis and progression in many cancers6. As first described in 1920s, some tumour cells preferentially rely on glycolysis rather than OXPHOS, even in conditions with ample oxygen (“aerobic glycolysis” or “Warburg effect”)7. While previous studies have paid much attention to abnormal glycolysis, little effort has been made to understand the role of gluconeogenesis, the reciprocal metabolic process of glycolysis, in cancer. Fructose-1,6-bisphosphatase (FBP1),
one of the rate-limiting enzymes in gluconeogenesis, catalyses the hydrolysis of fructose-1,6-bisphosphate (F-1,6-P2) to fructose 6-phosphate (F-6-P) and inorganic phosphate. Recently, FBP1 was reported to play suppressive–suppressive roles in several cancers, including renal cancer, breast cancer, lung cancer, pancreatic cancer and gastric cancer. Until now, the most important mechanism underlying FBP1 suppression was reported to be promoter DNA methylation. However, the role and mechanism of dysregulated FBP1 in HCC remain far from clear. We conducted this study to clarify the role of FBP1 in Snail-induced EMT and the prognostic role of FBP1 in HCC.

Materials and methods
Clinical specimens, tissue microarray and immunohistochemistry
All patients were enrolled from the First Affiliated Hospital of Sun Yat-sen University between January 2006 and December 2009. The median follow-up for the 242 patients was 31.0 months (range, 3–95 months). Patients were staged according to the seventh edition of the International Union Against Cancer TNM classification system. All protocols were approved by the Ethics and Indications Committee of the First Affiliated Hospital of Sun Yat-sen University. Written informed consent was obtained from all patients.

A tissue microarray (TMA) of 242 pairs of HCCs and corresponding peritumoural tissues was constructed. The tissue samples were incubated with anti-Snail (Abcam, Ab180714), anti-FBP1 (Abcam, Ab180714), anti-E-cadherin (Cell Signaling Technology, 9782), and anti-Vimentin (Cell Signaling Technology, 9782) antibodies overnight at 4 °C. Negative controls were performed without primary antibodies. Three representative fields were imaged in a uniform setting for all slides. Image-Pro Plus v6.2 software (Media Cybernetics Inc., Bethesda, MD) was used to measure the density of positive staining. The median values were defined as the cutoff values for high and low Snail or FBP1 expression.

Cell culture
Seven human liver cancer cell lines (Bel-7402, Hep3B, HepG2, MHCC-97H, MHCC-97L, PLC/PRF/5 and SMMC-7721) were used for the analyses. All cell lines were obtained from the Chinese Academy of Sciences. Unless specifically indicated, cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% foetal bovine serum (Gibco, USA) at 37 °C with 5% CO2 and 95% humidity. Quantitative real-time PCR (qRT-PCR) total RNA was extracted with a TRIzol (Gibco, USA) protocol and reverse transcribed into complementary DNA (cDNA) using the RevertAid TM First Strand cDNA Synthesis kit (Thermo, USA). qRT-PCR was performed using the BestarSybrGreen qPCR master mix kit (DBI, Germany) and BIO-RAD IQ5qRT-PCR System (Bio-Rad, USA). Next, mRNA levels were normalised against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-tubulin. The following primers were used: human Snail, forward 5ʹ-CAATCGGAAGCCCTAACTACAGC-3ʹ and reverse 5ʹ-GACAGAGTCCCAGATGAGA-3ʹ; human E-cadherin, forward 5ʹ-GGGTTATTCCTCCATACGC-3ʹ and reverse 5ʹ-GTCACCTTCGACCATCCTGT-3ʹ; human Vimentin, forward 5ʹ-AAGAGAACCTTTCGTTGAAG-3ʹ and reverse 5ʹ-ACGAGGCTTGGATTG-3ʹ; human FBP1, forward 5ʹ-GATTTGTCCGTGCCTGTTG-3ʹ and reverse 5ʹ-TGCCATACAGTCGCGTGACC-3ʹ; human GAPDH, forward 5ʹ-GAGGATTGTGCTGCTTG-3ʹ and reverse 5ʹ-TGCAAGTTGAAAGGAGATCATC-3ʹ. The 2–ΔΔCT method was used for quantification.

Western blotting analyses
Cultured cell lysates were prepared using RIPA buffer and Phenylnemethanesulfonyl fluoride (PMSF) (both from Beyotime, Nantong, China) and then separated on 10% Sodium dodecyl sulfate (SDS) polyacrylamide gels. Primary antibodies against Snail (Abcam, Ab180714), FBP1 (Abcam, Ab180714), E-cadherin (Cell Signaling Technology, #9782), Vimentin (Cell Signaling Technology, #9782), Slug (Cell Signaling Technology, #9782), zinc-finger E-box-binding homeobox 1 (ZEB1; Abcam, Ab155249) and Twist1 (Abcam, Ab187008) were used. Protein levels were normalised against β-tubulin.

Cells transfection
The lentiviral-mediated GV320-FBP1 and Penti 5.0-CMV-Snail plasmids were constructed (Shanghai Genechem Co. Ltd). All stably transfected clones were confirmed by qRT-PCR and immunoblotting.

Transwell migration assay
A total of 5 × 10⁵ cells/well in serum-free DMEM were seeded into the upper chamber of an 8-µm transwell chamber (Beckton Dickinson, Franklin Lakes, NJ, USA); DMEM with 10% bovine serum albumin (BSA) was added in the lower chamber. After 24-h incubation at 37 °C, the cells in the upper chamber were fixed in methanol and then stained with Giemsa solution (Beyotime, Nantong, China). Then, the migrated cells were imaged and quantified.

CCK8 assay
A total of 1 × 10⁵ cells/well were cultured in 96-well plates. The CCK8 reagent was incubated into each well for 3 h at 37 °C and after 24 h, 48 h, 72 h and 96 h, the Cell Counting Kit-8 was used (Dojindo, Japan). The absorbency of cells at 450 nm was measured using the BioTek Epoch automatic enzyme-labelled instrument (Biotek, USA).
Immunofluorescence assay

Cells were cultured in six-well plates. After incubation for 48 h, cells were washed with phosphate-buffered saline, fixed with 4% paraformaldehyde, blocked with 5% BSA, stained with E-cadherin and Vimentin, and then stained with Fluorescein isothiocyanate (FITC)-labelled secondary antibody and 4',6-diamino-2-phenylindole (DAPI) as per the manufacturer’s instructions (Beyotime, Nantong, China). The images were captured using fluorescence microscope.
Orthotopic transplantation HCC mouse models

Male BALB/c nude mice, aged 4–6 weeks, were used. A total of $2 \times 10^6$ tumour cells were injected into subcutaneous regions of nude mice. Subcutaneous tumour tissues with a longitudinal diameter of 1 cm were harvested and were cut into approximately 1 mm$^3$ pieces. Then, tumour pieces were transplanted into the left hepatic lobe of the mice. All mice were sacrificed 6 weeks later and analysed. All mice were obtained from Shanghai Institute of Material Medicine and maintained in a pathogen-free environment. Animal care and experimental protocols were in accordance with the guidelines established by Shanghai Medical Experimental Animal Care Commission and were in accordance with regulations for the Administration of Affairs Concerning Experimental Animals and National Institutes of Health Guidelines.
Public clinical dataset analyses and gene set enrichment analyses (GSEA)

Gene expression and survival profiles, if available, were obtained from the National Cancer for Biotechnology Information Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds, RRID: SCR_005012) (accession number GSE14520, GSE54236, GSE25097)\(^{16–18}\). Moreover, mRNA expression and clinical data from 377 LIHC and 50 normal control samples were obtained from The Cancer Genome Atlas (TCGA, last download date: 2017.11.01) (http://cancergenome.nih.gov/, RRID: SCR_003193) and cBioportal for Cancer Genomics (last download date: 2017.11.01) (http://www.cbioportal.org/, RRID: SCR_014555)\(^{19,20}\). The exclusion criteria for clinical analyses were: (1) clinical information not confirmed, and (2) not available (NA) or \(-\text{infinite} (-\infty)\) gene expression values.

GSEA v3.0 (http://www.broadinstitute.org/gsea/, RRID: SCR_003199)\(^{21,22}\) was used to find terms predicted to be enriched in C2 (the Kyoto Encyclopaedia of Genes and Genomes pathway, KEGG), in C5 (a gene set that contained genes annotated by the same Gene Ontology (GO) term), and in C6 (oncogenic signatures of gene sets that represent the signatures of cellular pathways that are often dysregulated in cancer). Data from non-HCC patients were excluded. \(P<0.05\) and false discovery rate (FDR) \(q\)-value \(<0.25\) were considered statistically significant.

Statistical analysis

Statistical analyses were performed using SPSS V19.0 (SPSS Inc., USA), R software V3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and presented using GraphPad Prism v7.00 (GraphPad Software Inc.,
Fig. 5 (See legend on next page.)
USA). Qualitative variables were analysed using the Pearson χ² test or Fisher’s exact test. Quantitative variables were compared using t-test, Pearson’s correlation test or Spearman rank correlation analysis as appropriate. The survival analyses were plotted using the Kaplan–Meier method and were compared using the log-rank test. Multivariate analyses were performed using the Cox regression model method with forward stepwise procedure. P < 0.05 was considered statistically significant.

Results

FBP1 was suppressed during Snail-induced EMT
We first examined the expression of Snail using qRT-PCR in seven HCC cell lines: MHCC-97H, MHCC-97L, PLC/PRF/5, HepG2, Bel-7402, SMMC-7721 and Hep3B. SMMC-7721 cells expressed the lowest Snail level, whereas MHCC-97H cells expressed the highest (Fig. 1a). The SMMC-7721 cell line was selected for further experiments. We transfected SMMC-7721 cells with a Snail overexpression plasmid to enhance the expression of Snail (SMMC-7721-Snail cells) (Fig. 1b, h). Upregulation of Snail significantly enhanced cell migration (Fig. 1c) but not cell proliferation (Fig. 1d). Snail overexpression induced Vimentin but suppressed E-cadherin, indicating the induction of EMT (Fig. 1e, f, h).

Next, we tested FBP1 following Snail overexpression. As shown in Fig. 1g, h, Snail upregulation significantly inhibited FBP1 in SMMC-7721 cells. Taken together, these data show that overexpression of Snail expression promoted migration, induced EMT and suppressed FBP1 in HCC. Similar results were found in the Hep3B cell line (Supplemental Fig. 1).

Expression of FBP1 and EMT markers in multiple HCC cell lines
We analysed FBP1 expression by qRT-PCR and western blot in the five HCC cell lines MHCC-97H, MHCC-97L, HepG2, Hep3B and SMMC-7721. We observed that MHCC-97H cells with the highest Snail and Vimentin expressed the lowest FBP1 and E-cadherin, but SMMC-7721 cells with the lowest Snail and Vimentin significantly expressed FBP1 and E-cadherin (Fig. 2a, b).

Ectopic FBP1 expression suppressed Snail-induced EMT and tumour growth in HCC
To further investigate the role of FBP1 in Snail-induced EMT, we upregulated FBP1 expression using the FBP1 overexpression plasmid in SMMC-7721-Snail cells (SMMC-7721-snail-FBP1). SMMC-7721-snail-FBP1 cells expressed higher E-cadherin (Fig. 3a) and appeared more like epithelial cells (Fig. 3b) than SMMC-7721-Snail cells. FBP1 expression significantly inhibited cell migration induced by Snail overexpression (Fig. 3c).

Then, orthotopic transplantation HCC mouse models were established. Overexpression of Snail promoted tumour growth and inhibited E-cadherin (Fig. 3d, e, f). A subcutaneous tumour formation experiment using Hep3B cells revealed similar results (Supplemental Fig. 2). However, ectopic FBP1 significantly inhibited Snail-induced tumour growth (Fig. 3d, e, f) and rescued E-cadherin expression (Fig. 3g). Collectively, these data suggested that FBP1 suppressed Snail-induced EMT, migration and tumour growth in HCC.

GSEA of TCGA dataset
To further understand the underlying molecular mechanisms of dysregulated FBP1 and Snail, we performed GSEA analyses using data from TCGA LIHC dataset. The expression data of 24,991 genes from 361 HCC patients were included in our analyses. We aimed to identify terms differing between the high (top 10%) and low (bottom 10%) expressing groups of FBP1 and Snail. As FBP1 was suppressed by Snail expression in HCC, we explored the enriched terms overlapping in the high Snail and low FBP1 groups.

GO terms such as anchoring junction, apoptotic signalling pathway, cell ageing, cytoplasmic region, cell substrate junction, enhancer binding, FC receptor signalling pathway, hippo signalling, positive regulation of cytoplasmic transport, positive regulation of proteolysis, protein dephosphorylation, regulation of defence response to virus, Ras protein signal transduction, KEGG pathways involving WNT signalling pathway, Notch signalling pathway and pathogenic Escherichia coli infection were significantly enriched in the high Snail or low FBP1 group when compared with the low Snail or high FBP1 group, respectively. Moreover, oncological signatures
Early serum response (CSR), Dichloroacetate (DCA), Embryonic stem cells (ESC) and Platelet-derived growth factor (PDGF) were found to be significantly associated with high Snail, as well as low FBP1 (Fig. 4, Supplemental Table 1).

FBP1 was suppressed in HCC patients and indicated prognosis

We analysed the mRNA expression profile of FBP1 in human HCC using data available in the GEO database, including GSE14520, GSE54236, GSE25097 and TCGA HCC. FBP1 mRNA was found to be significantly suppressed in HCC when compared with non-tumour controls (Fig. 5a).

We then examined the expression of FBP1 in 242 patients from our hospital (Fig. 5b) and classified patients into low and high FBP1 groups using median values as described above. Low FBP1 expression was significantly correlated with alpha-fetoprotein (AFP) ≥ 20 ng/ml (P = 0.026), portal vein tumour thrombus (PVTT) (P = 0.020), satellite nodule (P = 0.006), advanced TNM stage (P = 0.001) and advanced Barcelona Clinic Liver Cancer stage (BCLC stage; P = 0.001) (Table 1). Kaplan–Meier analyses showed that the 1-, 3-, and 5-year recurrence-free survival (RFS) rates for the high and low FBP1 expression groups were 57.9%, 43.0% and 37.9%, and 31.4%, 20.7% and 18.1%, respectively (P < 0.001). The 1-, 3-, and 5-year overall survival (OS) rates for the high and low FBP1 expression groups were 81.8%, 61.2% and 52.0%, and 56.2%, 32.2% and 28.9%, respectively (P < 0.001) (Fig. 5c). These were further corroborated by results of the Cox proportional hazard regression analyses, which revealed that FBP1 expression was an independent prognostic indicator.

### Table 1 FBP1 expression and clinicopathological characteristics of 242 HCC patients

| Factors | FBP1<sub>low</sub> (n = 121) | FBP1<sub>high</sub> (n = 121) | P-value |
|---------|----------------------------|----------------------------|---------|
| Sex     | 106 (Male) 15 (Female)     | 107 (Male) 14 (Female)     | 0.843   |
| Age (years) ≤ 50 | 60 | 61 | 0.898 |
| HbsAg positive | Yes 110 | No 11 | 0.119 |
| HCV positive | Yes 1 | No 120 | 1.000 |
| ALT (IU/L) <40 | 61 | 64 | 0.700 |
| Tbil (μmol/L) ≥17 | 44 | 33 | 0.129 |
| ALB (g/L) <35 | 9 | 5 | 0.271 |
| AFP (ng/ml) <20 | 23 | 38 | 0.026 |
| Cirrhosis | Yes 97 | No 24 | 0.437 |
| Tumour diameter ≤5 cm | 36 | 48 | 0.105 |
| Tumour capsule | Yes 71 | No 50 | 0.060 |
| Satellite nodules | Yes 48 | No 73 | 0.006 |
| PVTT yes | 29 | 15 | 0.020 |

**Table 1 continued**

| Factors | FBP1<sub>low</sub> (n = 121) | FBP1<sub>high</sub> (n = 121) | P-value |
|---------|----------------------------|----------------------------|---------|
| Edmonson grade | I-II 93 | III+IV 28 | 0.641 |
| TNM stage | I 60 | II+III+IV 61 | 0.001 |
| BCLC stage | A 62 | B+C 59 | 0.001 |

**AFP** alpha-fetoprotein, **ALT** alanine aminotransferase, **ALB** albumin, **BCLC stage** Barcelona Clinic Liver Cancer stage, **FBP1** fructose-1,6-bisphosphatase 1, **HBV** hepatitis B virus, **HCV** hepatitis C virus, **TNM stage** tumour-node-metastasis stage, **PVTT** portal vein tumour thrombosis

All the bold P-value were less than 0.05.

FBP1 was suppressed in HCC patients and indicated prognosis

We analysed the mRNA expression profile of FBP1 in human HCC using data available in the GEO database, including GSE14520, GSE54236, GSE25097 and TCGA HCC. FBP1 mRNA was found to be significantly suppressed in HCC when compared with non-tumour controls (Fig. 5a).

We then examined the expression of FBP1 in 242 patients from our hospital (Fig. 5b) and classified patients into low and high FBP1 groups using median values as described above. Low FBP1 expression was significantly correlated with alpha-fetoprotein (AFP) ≥ 20 ng/ml (P = 0.026), portal vein tumour thrombus (PVTT) (P = 0.020), satellite nodule (P = 0.006), advanced TNM stage (P = 0.001) and advanced Barcelona Clinic Liver Cancer stage (BCLC stage; P = 0.001) (Table 1). Kaplan–Meier analyses showed that the 1-, 3-, and 5-year recurrence-free survival (RFS) rates for the high and low FBP1 expression groups were 57.9%, 43.0% and 37.9%, and 31.4%, 20.7% and 18.1%, respectively (P < 0.001). The 1-, 3-, and 5-year overall survival (OS) rates for the high and low FBP1 expression groups were 81.8%, 61.2% and 52.0%, and 56.2%, 32.2% and 28.9%, respectively (P < 0.001) (Fig. 5c). These were further corroborated by results of the Cox proportional hazard regression analyses, which revealed that FBP1 expression was an independent prognostic indicator.

**Table 1**

| Factors | FBP1<sub>low</sub> (n = 121) | FBP1<sub>high</sub> (n = 121) | P-value |
|---------|----------------------------|----------------------------|---------|
| Sex     | 106 (Male) 15 (Female)     | 107 (Male) 14 (Female)     | 0.843   |
| Age (years) ≤ 50 | 60 | 61 | 0.898 |
| HbsAg positive | Yes 110 | No 11 | 0.119 |
| HCV positive | Yes 1 | No 120 | 1.000 |
| ALT (IU/L) <40 | 61 | 64 | 0.700 |
| Tbil (μmol/L) ≥17 | 44 | 33 | 0.129 |
| ALB (g/L) <35 | 9 | 5 | 0.271 |
| AFP (ng/ml) <20 | 23 | 38 | 0.026 |
| Cirrhosis | Yes 97 | No 24 | 0.437 |
| Tumour diameter ≤5 cm | 36 | 48 | 0.105 |
| Tumour capsule | Yes 71 | No 50 | 0.060 |
| Satellite nodules | Yes 48 | No 73 | 0.006 |
| PVTT yes | 29 | 15 | 0.020 |

**AFP** alpha-fetoprotein, **ALT** alanine aminotransferase, **ALB** albumin, **BCLC stage** Barcelona Clinic Liver Cancer stage, **FBP1** fructose-1,6-bisphosphatase 1, **HBV** hepatitis B virus, **HCV** hepatitis C virus, **TNM stage** tumour-node-metastasis stage, **PVTT** portal vein tumour thrombosis

All the bold P-value were less than 0.05.

FBP1 was suppressed in HCC patients and indicated prognosis

We analysed the mRNA expression profile of FBP1 in human HCC using data available in the GEO database, including GSE14520, GSE54236, GSE25097 and TCGA HCC. FBP1 mRNA was found to be significantly suppressed in HCC when compared with non-tumour controls (Fig. 5a).

We then examined the expression of FBP1 in 242 patients from our hospital (Fig. 5b) and classified patients into low and high FBP1 groups using median values as described above. Low FBP1 expression was significantly correlated with alpha-fetoprotein (AFP) ≥ 20 ng/ml (P = 0.026), portal vein tumour thrombus (PVTT) (P = 0.020), satellite nodule (P = 0.006), advanced TNM stage (P = 0.001) and advanced Barcelona Clinic Liver Cancer stage (BCLC stage; P = 0.001) (Table 1). Kaplan–Meier analyses showed that the 1-, 3-, and 5-year recurrence-free survival (RFS) rates for the high and low FBP1 expression groups were 57.9%, 43.0% and 37.9%, and 31.4%, 20.7% and 18.1%, respectively (P < 0.001). The 1-, 3-, and 5-year overall survival (OS) rates for the high and low FBP1 expression groups were 81.8%, 61.2% and 52.0%, and 56.2%, 32.2% and 28.9%, respectively (P < 0.001) (Fig. 5c). These were further corroborated by results of the Cox proportional hazard regression analyses, which revealed that FBP1 expression was an independent prognostic indicator.

**Table 1**

| Factors | FBP1<sub>low</sub> (n = 121) | FBP1<sub>high</sub> (n = 121) | P-value |
|---------|----------------------------|----------------------------|---------|
| Edmonson grade | I-II 93 | III+IV 28 | 0.641 |
| TNM stage | I 60 | II+III+IV 61 | 0.001 |
| BCLC stage | A 62 | B+C 59 | 0.001 |

**AFP** alpha-fetoprotein, **ALT** alanine aminotransferase, **ALB** albumin, **BCLC stage** Barcelona Clinic Liver Cancer stage, **FBP1** fructose-1,6-bisphosphatase 1, **HBV** hepatitis B virus, **HCV** hepatitis C virus, **TNM stage** tumour-node-metastasis stage, **PVTT** portal vein tumour thrombosis

All the bold P-value were less than 0.05.
factor for RFS and OS (P < 0.001 and P = 0.001, respectively) (Supplemental Table 2, Table 2). To confirm our results, we then analysed the public dataset GSE14520. In accordance with our cases, low FBP1 expression was correlated with higher AFP level (P = 0.001), advanced TNM stage (P = 0.022) and advanced BCLC stage (P = 0.006). Low FBP1 expression was found to be correlated with larger tumour size (P = 0.014) (Supplemental Table 3). Low FBP1 expression was significantly associated with poorer RFS and OS (P < 0.001 and P = 0.004, respectively) (Fig. 5d). FBP1 expression was also an independent prognostic factor for OS in this cohort (Supplemental Table 4). Collectively, low FBP1 expression indicated poorer prognosis for HCC patients.

Prognostic role of FBP1 and Snail

We investigated the expression of Snail mRNA in GSE14520, GSE54236, GSE25097 and TCGA HCC datasets. As shown in Fig. 6a, Snail mRNA was lower in tumour than non-tumour tissue, and no significant correlation between FBP1 and Snail mRNA was found. We then examined the expression of Snail in our cohort (Fig. 6b). An almost but not quite significant correlation between FBP1 and Snail mRNA was found (R = -0.091, Pearson correlation P = 0.079). Patients were further divided into four groups: SnailhighFBP1high, SnaillowFBP1high, SnailhighFBP1low and SnaillowFBP1low. We found that the prognosis of patients in the SnaillowFBP1high group tended to be the best, whereas the prognosis of patients in the SnailhighFBP1low tended to be the worst among the four groups (Fig. 6c, d). Similar results were found in the GSE14520 cohort (Fig. 6e, f).

Discussion

Mounting evidence shows the critical role of aerobic glycolysis in tumourigenesis and progression of cancer9,13. In contrast, few studies directly focus on the role of aberrant gluconeogenesis in cancers. Here, we observed suppression of FBP1 during Snail-induced EMT in HCC. We revealed that forced expression of FBP1 repressed the EMT phenotype, HCC migration and tumour growth induced by Snail overexpression. We elucidated several significantly enriched terms, KEGG pathways and oncological signatures in the high Snail and low FBP1 group when compared with the low Snail and high FBP1 group. Last but not least, FBP1 expression was found to be an independent prognostic factor for RFS and OS in HCC. FBP1 dysregulation provided metabolic advantages and promoted cancer progression in various cancers, including renal cancer8, breast cancer9, HCC19, lung cancer10, pancreatic cancer11,12 and gastric cancer13. For example, Li et al. reported that FBP1 hindered renal carcinoma progression by inhibiting Hypoxia-inducible factor (HIF)-1α (HIF1α) activity in the nucleus via a direct interaction in an enzyme-activity-independent manner8. FBP1 suppression resulted in an increased cancer stem cell (CSC)-like phenotype and tumourigenesis by enhancing the interaction of β-catenin with T-cell factor in basal-like breast cancer cells9. FBP1 overcame gemcitabine resistance and inhibited extracellular regulated protein kinases (ERK) activation by blocking IQ motif containing GTPase-activating protein 1 (IQGAP1)–mitogen-activated protein kinase (MAPK) interaction in pancreatic cancer cells12. Low FBP1 expression was found to be an independent factor for poorer survival, which were consistent with previous

| Factors                                      | RFS HR (95% CI) | P-value | OS HR (95% CI) | P-value |
|----------------------------------------------|----------------|---------|----------------|---------|
| ALB: ≥ 35 vs < 35 g/L                        | -              |         | 0.457 (0.249–0.839) | 0.011   |
| Tumour size: > 5 vs ≤ 5 cm                   | 1.997 (1.408–2.832) | <0.001 | 1.933 (1.313–2.844) | 0.001   |
| Encapsulation: complete vs incomplete or absence | 0.684 (0.490–0.954) | 0.025   | 0.662 (0.472–0.930) | 0.017   |
| Satellite nodules: yes vs no                 | -              |         | -              |         |
| PVTT: yes vs no                              | 1.565 (1.006–2.436) | 0.047   | -              |         |
| Edmonson grade: III+IV vs I+II               | -              |         | -              |         |
| TNM: II+III+IV vs I                          | -              |         | -              |         |
| BCLC: B+C vs A                               | 1.704 (1.182–2.456) | 0.004   | 2.414 (1.690–3.447) | <0.001  |
| FBP1 expression: high vs low                 | 0.576 (0.424–0.784) | <0.001 | 0.582 (0.418–0.809) | 0.001   |

ALB albumin, FBP1 fructose-1,6-bisphosphatase 1, BCLC stage Barcelona Clinic Liver Cancer stage, TNM stage tumour-node-metastasis stage, PVTT portal vein tumour thrombus
Fig. 6 (See legend on next page.)
An oncogenic role for FBP1. All these results implicate survival of breast cancer brain metastatic cells, indicating that FBP1 expression improved viability and deterioratedpressive factor in cancer. In contrast, Chen et al. reported HCC. From this point of view, FBP1 could serve as sup-

should be made to validate these studies, as well as analyses from public datasets in HCC. From this point of view, FBP1 could serve as suppressive factor in cancer. In contrast, Chen et al. reported that FBP1 expression improved viability and deteriorated survival of breast cancer brain metastatic cells, indicating an oncogenic role for FBP1. All these results implicate that FBP1 exerts different roles in different tissues and stages of cancer.

Promoter DNA methylation is the best understood mechanism for FBP1 loss in cancer. The Rat Sarcoma (RAS)/NF-kB: nuclear factor-kappa B (NF-kB) pathway promoted DNA methylation of FBP1 in gastric cancer cells. The Snail-G9a-Dnmt1 complex, which is critical for E-cadherin promoter silencing, was also responsible for the promoter methylation of FBP1 in basal-like breast cancer cells. ZEB1 interacted with the FBP1 promoter to enhance DNA methylation in lung cancer cells. NPM1 bound directly to the FBP1 promoter region to suppress the expression of FBP1 in pancreatic cancer cells. In addition, copy number loss and post-translational ubiquitin-mediated degradation were also found to be associated with FBP1 loss. Thus, a complicated and multilayer regulatory network exists for the suppression of FBP1 in cancer, which remains to be clarified.

EMT promotes malignant tumour progression and chemoresistance. As a well-known major driver of EMT, Snail expression has been reported to be correlated with cancer metastasis and poorer survival. Our findings indicated the critical role of FBP1 in Snail-induced EMT and cancer progression in HCC, which is similar to that in breast cancer and gastric cancer. Furthermore, GSEA indicated several enriched pathways deserving to be explored to explain the underlying mechanism of dysregulated FBP1 suppression. For example, the ERK and WNT pathways have been demonstrated to be involved in FBP1 regulation in cancers. However, much effort should be made to validate these findings from GSEA.

Several questions remain to be further investigated. First, it is a limitation that we lack biochemical evidence showing that our ectopic FBP1 was enzymatically active. Whether FBP1 enzymatic activity or any other enzyme-activity-independent mechanism plays critical role in Snail-induced EMT remained to be clarified. Second, we found that FBP1 did not affect the expression of Snail, raising the question of how FBP1 suppressed the transcriptional activity of Snail. Two different mechanisms might help explain the phenomenon. One possibility is that FBP1 participates in a Snail subcellular location mechanism, such as nuclear transport, and then modulates Snail stability. Another possibility is that FBP1 directly inhibits the Snail functional domain in the nucleus, similar to HIF in renal cancer. Clarifying the subcellular location of FBP1 in Snail-induced EMT is critical to understanding the detailed interaction of Snail and FBP1. Last but not least, we found no significant correlation between FBP1 and Snail mRNA in HCC patients. The results must be explained with great caution. The difference between in vivo and in vitro experiments might be due to the underlying baseline characteristics (HCC aetiology, patient ethnicity, related-related characteristics) and need to be further validated.

Conclusions

In summary, our study demonstrated that FBP1 was suppressed in Snail-induced EMT and HCC patients. Ectopic FBP1 expression hindered EMT and tumour growth induced by Snail overexpression. Several pathways, such as ESC, CSR and PDGF, could be further explored to explain the underlying mechanisms of FBP1 dysregulation. Loss of FBP1 indicated poorer prognosis and was an independent prognostic factor of HCC. Our study revealed an important role for FBP1 in Snail-induced EMT and prognostic prediction in HCC.

Acknowledgements

This project was supported by grants from the National Nature Science Foundation of China (no. 81502526).

Authors’ contributions

B.-G.P. conceived, designed and revised the manuscript. X.-Y.H. conceived, designed, and performed the experiments and revised the manuscript. G.-M.L., Q.-L. and P.-F.Z. performed the experiments and contributed to the analysis of data and writing of the manuscript. S.-L.S. and W.-X.X. provided technical support, performed the experiments and analysed the data. B.C., J.W. and W.-J.H. supervised the study, managed the patients, and provided the tissue specimens and HCC cell lines. All authors read and approved the final manuscript.

Author details

1Department of Liver Surgery, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Er Road, 510080 Guangzhou, China. 2Department of
of Hepatobiliary Surgery, Meizhou People’s Hospital, No. 34 Huangtang Road, S14031 Meizhou, China. §Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-018-1165-x).

Received: 23 April 2018 Revised: 26 September 2018 Accepted: 16 October 2018 Published online: 14 November 2018

References
1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
2. Wang, X., Zhang, A. & Sun, H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatol. (Baltim., MD) 57, 2072–2077 (2013).
3. De Caene, B. & Rex, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97–110 (2013).
4. Thiery, J. P. Epithelial-mesenchymal transitions in tumor progression. Nat. Rev. Cancer 2, 442–454 (2002).
5. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3, 155–166 (2002).
6. Petersen, M. C., Vamer, D. F. & Shulman, G. I. Regulation of hepatic glucose metabolism in health and disease. Nat. Rev. Endocrinol. 13, 572–587 (2017).
7. Warburg, O. On the origin of cancer cells. Sci. (New York, NY) 123, 309–314 (1956).
8. Li, B. et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature 513, 251–255 (2014).
9. Dong, C. et al. Loss of FBPI by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23, 316–331 (2013).
10. Zhang, J. et al. Down-regulation of FBPI by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol. Cell. Biochem. 411, 331–340 (2016).
11. Zhu, Y. et al. NPM1 activates metabolic changes by inhibiting FBPI while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget 6, 21449–21451 (2015).
12. Jin, X. et al. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Cancer research, 77, 4328-4341 (2017).
13. Liu, X. et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 29, 442–450 (2010).
14. Chen, M. et al. Promoter hypermethylation mediated downregulation of FBPI in human hepatocellular carcinoma and colon cancer. PLoS ONE 6, e25564 (2011).
15. Pan, D., Mao, C. & Wang, Y. X. Suppression of gluconeogenic gene expression by LSD1-mediated histone demethylation. PLoS ONE 8, e66294 (2013).
16. Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70, 10202–10212 (2010).
17. Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765–769 (2012).
18. Villa, E. et al. Neangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65, 861–869 (2016).
19. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
20. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pi1 (2013).
21. Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267 (2003).
22. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
23. Ma, R. et al. Switch of glycolysis to gluconeogenesis by dexamethasone for treatment of hepatocarcinoma. Nat. Commun. 4, 2508 (2013).
24. Hirata, H. et al. Decreased expression of fructose-1,6-bisphosphatase associates with glucose metabolism and tumor progression in hepatocellular carcinoma. Cancer Res. 76, 3265–3276 (2016).
25. Liu, G. M. & Zhang, Y. M. Targeting FBPIase is an emerging novel approach for cancer therapy. Cancer Cell Int. 18, 36 (2018).
26. Ninouso, Z. et al. Identification of the consistently altered metabolic targets in human hepatocellular carcinoma. Cell Mol. Gastroenterol. Hepatol. 4, 303–323 (2017). e301.
27. Chen, J. et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015).
28. Jin, X., Pan, Y. & Wang, L. MAGE-TRIM28 complex promotes the Warburg effect and hepatocellular carcinoma progression by targeting FBPI for degradation. Oncogene 36, e312 (2017).
29. Yang, M. et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology 50, 1464–1474 (2009).
30. Yu, J. et al. Snail enhances glycolysis in the epithelial-mesenchymal transition process by targeting FBPI in gastric cancer. Cell Physiol. Biochem. 43, 31–38 (2017).
31. Muzibil, I., Wu, J., Aboukameel, A., Mohammad, R. & Azmi, A. Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition? Semin. Cancer Biol. 27, 39–45 (2014).